Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro Inc (NQ: ALZN )

0.7300 -0.0430 (-5.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 275,599
Open 0.7700
Bid (Size) 0.7300 (63)
Ask (Size) 0.7458 (8)
Prev. Close 0.7730
Today's Range 0.7161 - 0.7900
52wk Range 0.3105 - 1.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
These biotech stocks with high return potential are poised to provide quick returns for investors who invest over the next year. 
Via InvestorPlace
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
These 3 penny stocks have 10X potential over the next twelve months, providing the right risk/reward bet for certain investors. 
Via InvestorPlace

Performance

YTD
+25.86%
+25.86%
1 Month
+45.68%
+45.68%
3 Month
+30.36%
+30.36%
6 Month
-36.52%
-36.52%
1 Year
-23.52%
-23.52%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
Via Benzinga
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Ault Alliance, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine
Via Benzinga
EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
Via Benzinga
KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Via Business Wire
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia
Via Benzinga
Alzamend Neuro to Present at Sequire Biotechnology Conference
From Alzamend Neuro, Inc.
Via Business Wire
SEC Goes After 'MrZackMorris, 'Stock Sniper' For Alleged Fraud
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
From Alzamend Neuro, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.